Discernment between candidate mechanisms for KRAS G13D colorectal cancer sensitivity to EGFR inhibitors

Phase three clinical trial evidence suggests that colorectal cancers with the KRAS G13D mutation may benefit from EGFR inhibitors, like cetuximab, in contrast to the other most common KRAS mutations. A mechanism to explain why this mutation behaves differently from other KRAS mutations had long been...

Full description

Saved in:
Bibliographic Details
Published in:Cell Commun Signal
Main Authors: McFall, Thomas, Schomburg, Noah K., Rossman, Kent L., Stites, Edward C.
Format: Artigo
Language:Inglês
Published: BioMed Central 2020
Subjects:
Short Report
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7643456/
https://ncbi.nlm.nih.gov/pubmed/33153459
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12964-020-00645-3
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items